AQST

Aquestive Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 1/10
  • Momentum↑ 5/10
Aquestive Therapeutics sales and earnings growth
AQST Growth
Low
  • Revenue Y/Y↓ -26.32%
  • EPS Y/Y↓ -54.35%
  • FCF Y/Y↓ -48.21%
Aquestive Therapeutics gross and profit margin trends
AQST Profitability
Low
  • Gross margin ↑ 60.30%
  • EPS margin↓ -158.90%
  • ROIC↓ -38.10%
Aquestive Therapeutics net debt vs free cash flow
AQST Risk
Great
  • Debt / Equity↓ -31.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -3.0

Aquestive Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗